GenePOC® Launches its GenePOC® CDiff Test in Canada

Tuesday, October 23, 2018 Hospital News
Email Print This Page Comment bookmark
Font : A-A+

GenePOC announces the Health Canada approval and launch of its molecular diagnostic test for the detection of Clostridium difficile in Canada

QUÉBEC CITY, Oct. 23, 2018 /PRNewswire/ -- GenePOC Inc., member of the Debiopharm Group, is proud to announce the approval by Health Canada and the launch

of its GenePOC CDiff assay to be used with the revogene™ instrument.

About the Clostridium difficile infection (CDI)In Canada, CDI is the main cause of infectious diarrhea in hospitals and long-term care facilities. In 2017, the INSPQ estimated that the incidence of C. Difficile nosocomial infections had reached up to 6.08 cases per 10 000 days-attendance. The mortality rates at 10 and 30 days were 6.3% and 12.4%, respectively1. Still today, CDI represents a major issue for many medical institutions and is associated with 260 million dollars in additional health care costs2.

About GenePOC CDiff assay and the revogene instrumentThe GenePOC CDiff assay is a qualitative in vitro diagnostic test to detect the toxin B (tcdB) gene of toxigenic C. difficile in stool specimens obtained from patients suspected of having CDI.

"The approval of our CDiff assay by Health Canada for the diagnostic of toxigenic C. difficile is in line with the objectives of control and prevention of this nosocomial infection. Within only seventy minutes, a CDI can be identified. Our molecular tests have demonstrated to provide specific, sensitive and timely identification of patients with toxigenic CDI. Moreover, they are easy to use and affordable."- Patrice Allibert, PhD, CEO of GenePOC

"C. difficile kills approximately 3000 Canadians a year. Rapid diagnosis using GenePOC's unique technology, initially developed in my laboratory at University Laval in Québec City, will save many lives while controlling its costly dissemination in hospitals."- Professor Michel G. Bergeron, M.D.

The GenePOC CDiff test has been developed with the financial support of the FPQIS (Fonds de partenariat pour un Québec en santé).

The revogene is an automated and stand-alone instrument. It enables testing of single-use proprietary microfluidic cartridges, called PIEs, with its fluorescence-based real-time polymerase chain reaction platform to deliver an accurate diagnosis.

About GenePOCGenePOC is a company that specializes in the development of diagnostic devices which enable the prevention and detection of infectious diseases. The company aims to become the market leader in rapid microbial testing. GenePOC is a member of the Debiopharm Group. GenePOC's revogene instrument is available in the US, EU and Canadian markets with a rapidly expanding test menu. Further information:

About Debiopharm GroupDebiopharm Group is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management.

For more information, please see

Debiopharm International SA Contact Christelle von BürenCommunication

GenePOC ContactPatrice Allibert,

  1. INSPQ Update July 24th 2017 (
  2. Levy and al., Open Forum Infect Dis 2015; 2: 1-10


Cision View original content:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store